The standard approach to Lyme disease — one antibiotic, taken orally for roughly three weeks — was developed based on the best available evidence for early, localised infection. It is the treatment most people receive when first diagnosed, and for a significant proportion of those people, it works.
This page explains what this treatment is, how it works, when it is most likely to be sufficient, and — with care and precision — what happens when it is not. This is not an argument against conventional medicine. It is an accurate picture of a treatment that has real strengths and real limits.
What the standard treatment is
The guidelines most widely used in mainstream medicine come from the Infectious Diseases Society of America (IDSA). These guidelines recommend a short course of a single oral antibiotic as first-line treatment for most presentations of Lyme disease.
The most commonly prescribed option. Oral, typically 100 mg twice daily. Recommended for adults and children over 8. Also has useful activity against Anaplasma, which may be co-transmitted.
Oral alternative for those who cannot take doxycycline — including pregnant women and young children.
Oral cephalosporin. A third recognised option in standard guidelines, used when doxycycline and amoxicillin are not suitable.
Intravenous. Reserved for confirmed Lyme neuroborreliosis, Lyme carditis with significant heart block, or clear failure of oral treatment.
Typically 10 to 21 days. 14 days is most common for erythema migrans (the bull's-eye rash). Up to 21 days for some neurological or cardiac presentations.
Borrelia burgdorferi is a bacterium. Antibiotics kill bacteria. In early, localised infection — when bacteria have not yet disseminated widely through body tissues — a targeted antibiotic course can clear the infection before it establishes itself more deeply. The clinical trial evidence supporting this in early Lyme is genuine and robust. The IDSA guidelines reflect that evidence accurately.
When standard treatment is most likely to be sufficient
The standard antibiotic course has the strongest track record in early, localised Lyme disease — when the infection is caught promptly and treated before it has had time to disseminate.
When Lyme disease is identified within days to a few weeks of the bite — ideally while the erythema migrans rash is still present — the infection is typically localised. The bacteria have not yet had time to spread to joints, the nervous system, or other tissues. In this window, a standard antibiotic course is highly effective.
When the diagnosis is clear — a visible rash, a known tick bite, positive serology, symptoms consistent with early Lyme — treatment can begin promptly and precisely. Clarity of diagnosis is a significant advantage that not all patients have.
When Borrelia is the only pathogen involved, a single antibiotic targeting that bacterium is appropriately focused. Co-infections — which require different drugs — do not complicate the picture.
Studies consistently show that the majority of people treated early for Lyme disease recover fully with a standard antibiotic course. This is not a small or trivial success rate. For many patients, this treatment is exactly what is needed, and it works.
Why Borrelia is a particularly difficult target
To understand where standard treatment can fall short, it helps to understand the biology of Borrelia burgdorferi. This is not a simple bacterium. It has evolved over millions of years as a parasite of mammals, and it has developed a range of mechanisms that allow it to persist under pressure — including antibiotic pressure.
What follows is established microbiological science — not fringe or contested. It is precisely the reason why the debate around treatment duration exists among researchers.
Under stress — including antibiotic exposure — Borrelia can convert from its active spiral form into dormant, spherical cysts. These are significantly more resistant to standard antibiotics, which target actively dividing bacteria. Cysts can later revert to active spirochetes when conditions improve.
Borrelia can form structured communities encased in a protective matrix on body tissues. Bacteria inside biofilms are shielded from both antibiotics and immune cells — biofilm-associated bacteria can be many times more resistant than free-living forms. This has been confirmed in Borrelia specifically in peer-reviewed research.
Borrelia has been shown to enter and survive inside human cells, including endothelial cells and macrophages. Inside a cell, bacteria are largely protected from antibiotics that do not penetrate intracellularly — which includes several commonly used Lyme treatments.
A small subpopulation of bacteria can enter a metabolically dormant state, making them highly tolerant to antibiotics without being genetically resistant. When the antibiotic course ends, persisters can reactivate and repopulate. This phenomenon — studied extensively at Johns Hopkins — is a recognised challenge in Lyme treatment.
Borrelia varies its surface proteins to avoid immune detection, suppresses aspects of the immune response, and preferentially resides in tissues with limited immune surveillance — including collagen-dense connective tissue and the central nervous system.
Borrelia divides far more slowly than most bacteria — approximately every 12–24 hours, versus minutes for common pathogens. Standard antibiotics are most effective against rapidly dividing cells. A short course may not expose the bacteria to the drug through enough replication cycles to achieve full eradication.
Cyst forms were first described in Borrelia in the 1990s. Biofilm formation has been confirmed by researchers at multiple institutions including the University of New Haven and Harvard. Persister cell research at Johns Hopkins (Feng et al., 2014 onwards) has directly informed ongoing treatment debates. These are published, peer-reviewed findings — not patient forum speculation.
When standard treatment may not be sufficient
Given the biological characteristics above, it is possible to understand — without contradicting mainstream science — why a short course of a single antibiotic may not resolve Lyme disease in every case. This is not a failure of the antibiotic itself. It is a mismatch between the tool and the situation it is being applied to.
When Lyme disease has been present for months or years before treatment begins — often because the bite was unnoticed, the rash did not appear, or early symptoms were attributed to other causes — the bacteria have had time to disseminate widely, form biofilms, and adopt survival forms. A three-week protocol designed for early localised infection is not calibrated for this situation.
Doxycycline has some activity against Anaplasma, but does not effectively treat Babesia (a parasite requiring entirely different drugs) or Bartonella (which often responds better to macrolides or specific combination protocols). When co-infections are present and untreated, symptoms attributed to "Lyme" may be driven primarily by pathogens the standard protocol does not address.
A proportion of patients — estimated between 10% and 20% in various studies — continue to experience significant symptoms after completing a standard antibiotic course. The mainstream position labels this Post-Treatment Lyme Disease Syndrome (PTLDS) and does not recommend further antibiotic treatment. An evidence-based alternative view, held by a growing number of researchers, holds that persistent infection may be a contributing factor in at least some of these cases. The debate is ongoing and unresolved.
If you completed a standard antibiotic course and still do not feel well, that outcome is not imagined — and it is not rare. Understanding the biology above may help make sense of why, and point toward what questions to ask next.
If standard treatment has not resolved your symptoms
Before assuming the Lyme itself is the unresolved problem, it is worth asking whether co-infections were identified and treated. Many clinicians test only for Borrelia — and even those tests have significant limitations. Bartonella and Babesia in particular can sustain a symptom picture that looks identical to persistent Lyme.
ILADS-affiliated physicians are more familiar with persistent infection, co-infection management, and longer or combination treatment approaches. The ILADS provider directory (ilads.org) is the most practical starting point. A second opinion does not replace your current clinician — it adds a more detailed map of a complex territory.
Regardless of which treatment path follows, the body needs support: restoring gut health after antibiotics, regulating the nervous system, improving sleep quality, and reducing systemic inflammation. These are not alternatives to treatment — they are the conditions that allow any treatment to work more effectively.
None of these steps require abandoning your current approach. They are about adding precision and context to whatever path you are already on.
Where to go next
ILADS-affiliated clinicians take a different approach — longer courses, combinations, and close attention to co-infections. Understanding how this differs from the standard approach helps you navigate the conversation with any practitioner.
Herbal protocols — including Buhner, Cowden, and others — are used by many people alongside or instead of antibiotics. Understanding what each one addresses helps you ask better questions about them.
Standard tests have real limitations — false negatives are common, and co-infections are often not tested at all. Understanding what your results mean — and don't mean — is essential context for any treatment decision.
Healing mentality checkpoint
For many people, discovering that the standard treatment was not enough brings a mix of relief — finally, an explanation — and deep frustration. Both are valid. Understanding the biology is not the same as having a solution. But it is the necessary first step toward finding one.
Read about healing mentality →A note on this information
- This page describes general patterns — not your specific situation or diagnosis.
- Standard guidelines exist because they are evidence-based. The purpose here is not to dismiss them but to present their context accurately.
- If you are currently being treated or have recently completed treatment, discuss any concerns with your clinician before making changes.
- If you feel your situation is not being adequately addressed, you are entitled to seek a second opinion.
Understanding the limits of a treatment is not the same as rejecting it. It is the beginning of a more precise conversation.
Sources & further reading
- Wormser G.P. et al. — IDSA clinical practice guidelines for Lyme disease (Clin Infect Dis, 2006; updated 2020)
- Feng J. et al. — Persister mechanisms in Borrelia burgdorferi (Antimicrob Agents Chemother, 2014)
- Sapi E. et al. — Characterization of biofilm formation by Borrelia burgdorferi in vitro (PLOS ONE, 2012)
- Meriläinen L. et al. — Morphological and biochemical features of Borrelia burgdorferi pleomorphic forms (Microbiology, 2015)
- Embers M.E. et al. — Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment (PLOS ONE, 2012)
- Klempner M.S. et al. — Two controlled trials of antibiotic treatment in patients with persistent symptoms and Lyme disease (NEJM, 2001)
- ILADS evidence-based guidelines — ilads.org/lyme-disease/ilads-guidelines
Last updated: March 2026